R. Trepiakas

发表

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.

I. Svane, S. Hadrup, A. Berntsen, 2010, Cytotherapy.

Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma: A Clinical Phase 1/2 trial

I. Svane, M. Claesson, A. Berntsen, 2008, Journal of immunotherapy.

Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function.

I. Svane, O. Met, A. Pedersen, 2009, Vaccine.

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study

H. Pappot, G. A. Taarnhøj, C. Suetta, 2020, European urology open science.

Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.

I. Svane, A. Berntsen, O. Met, 2008, Vaccine.

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.

A. Thiery-Vuillemin, A. Birtle, G. Ploussard, 2020, European urology.

Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study

A. Thiery-Vuillemin, A. Birtle, G. Ploussard, 2018, ESMO Open.

Variability in prostate and seminal vesicle delineations defined on magnetic resonance images, a multi-observer, -center and -sequence study

Tufve Nyholm, Per Bergström, Joakim Jonsson, 2013, Radiation oncology.

Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).

M. H. Poulsen, A. Birtle, G. Ploussard, 2018 .

CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.

N. Agarwal, T. Todenhöfer, A. Lithio, 2022, Journal of Clinical Oncology.